Navigation Links
Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting
Date:3/13/2008

ment for substantial funding to conduct research and development and to expand commercialization activities or consummate acquisitions; the accuracy of our estimations of the size of the market, and the potential market, for our products in specific disease areas; sales numbers and future guidance publicly provided by Boston Scientific Corporation regarding sales of their paclitaxel-eluting coronary stent products; and any other factors that may affect performance. In addition, our business is subject to certain operating risks that may cause the actual results expressed or implied by the forward-looking statements in this report to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete preclinical and clinical development of our products; changes in business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the ability of Boston Scientific Corporation to successfully manufacture, market and sell their paclitaxel-eluting coronary stent products; the continued availability of capital to finance our activities; our ability to achieve the financial benefits expected as a result of the acquisition of American Medical Instruments Holdings, Inc. ("AMI"); a
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2008)...all/ - Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS) today...ructuring plans to further reduce its cash burn ra...exploring strategic alternatives that may,include ... with this,process, the Company has also completed...d has determined that it is in the best interest o...
(Date:7/3/2008)...y, July 3,/- Rosetta Genomi...croRNA-based diagnostics and therapeutics, announc...nual Growth Conference on,Wednesday, July 9, at 8:...rk., About Rosetta Genomics, Rosetta Genomics (N...A.,Founded in 2000, the company,s integrative rese...
(Date:7/2/2008)...briva Therapeutics, a,specialist in antibiotics de...s been appointed as Chief Executive Officer of the...ly twenty years of industry,experience serving mos...nt,Licensing & Strategy for the oncology business...ible for the full array of business development,ac...
(Date:7/2/2008)...nstrate Superiority Over,Market-Leading Stent in C... Treatment of Coronary Artery Dis...Call/ -- Abbott today,announced that the U.S. Food...(TM) V Everolimus Eluting Coronary Stent System fo... V is the only drug eluting stent to have,demonstr...
Breaking Biology Technology:Vasogen Provides Corporate Update 2Nabriva Therapeutics Announces Appointment of New CEO 2FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent 2FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent 3FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent 4FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent 5
...son has made a deal with Georgia-based Cellnet t... the deployment will not be an overnight event. Ce..., starting with a 9-square-mile area around Capito...il in January and brought online in March. , ,Whil...brokering Cellnets access to city property and Mad...
... Technologies, former vice president Kevin Conroy ...ohn Puisis, who was CEO since mid-2004 and previou... resigned. , ,"I came to Third Wave and stayed for..."With a new business model and an upgraded, highly...s been completed." , ,Third Wave is one of the reg...
...hird Wave Technologies , compensation in a patent ...lus legal fees. Stratagene is proceeding with its ...ter the judge found that Stratagene willfully infr...s methods, and awarded Madison-based Third Wave $5...ts Invader line of products. Stratagene was given ...
...e Communications , which makes network hardware fo...federal appropriations to make battlefield communi... is part of the fiscal year 2006 Defense Appropria... Dave Obey, D-Wausau, with obtaining the funding o...e development of a faster and more secure communic...
Other Biology Technology:Madison wireless deal goes forward with Cellnet 2
(Date:7/3/2008)...rs of such marine creatures as clams, sand dollars...144 million years ago with no clear trend afterwar...ers. This contradicts previous work showing dramat...ay shed light on future diversity., "Some of the...s happening today from global warming," says Jocel...
(Date:7/3/2008)...m irrigation canal would seem a healthier place fo... , But University of Florida scientists have fou...ications for a longstanding debate over whether ag...UF zoologists have found that toads in suburban ar...stem abnormalities than toads near farms where so...
(Date:7/3/2008)... There,s little the average person can do to stem ...gas and other energy sources. But by improving our...k, we can use less energy and save money. , IEEE...n 20 June, says that, "Through energy efficiency i...osts; reduce the depletion of fuel resources; incr...
(Date:7/3/2008)... Kuijk has studied the regeneration of the tropica...oes regenerate to tropical forest, but only slowly...uning of foliage to free up space for trees and pl...e PHOLIAGE model to calculate the appropriate meas... the products and services the forest supplies. Ho...
Breaking Biology News(10 mins):Ancient marine invertebrate diversity less explosive than thought 2Ancient marine invertebrate diversity less explosive than thought 3New study points to agriculture in frog sexual abnormalities 2New study points to agriculture in frog sexual abnormalities 3IEEE-USA position encourages energy efficiency to save households money, reduce carbon emissions 2Giving nature a helping hand 2Consumer Groups Will Continue to Press Stem Cell Patent Challenge 13011 1Consumer Groups Will Continue to Press Stem Cell Patent Challenge 13011 2U of Minn researchers discover genetic cancer link between humans and dogs 13010 1U of Minn researchers discover genetic cancer link between humans and dogs 13010 2U of Minn researchers discover genetic cancer link between humans and dogs 13010 3Engineering the worlds fastest swimsuit 2343 1Engineering the worlds fastest swimsuit 2343 2Maternal love 3A How a mothers brain responds to her infant 13008 1Maternal love 3A How a mothers brain responds to her infant 13008 2
...earchers at SUNY Downstate Medical Center and the ...protein, PNC-28, is administered to pancreatic tum... research was reported in the October 1st edition ... R. Pincus, MD, PhD, professor of pathology at SUN...ry medicine at the Brooklyn VA, said, "The results...
...ew study on the ability of liver cells to interact...ulating the immune response) found that such inter... which they may take place. The results may help e...h aging and other conditions and may be useful in ...mmune diseases. , The results of this study appear...
... well an individual,s immune system controls HIV d...depend on both the specific versions of key immune...n inherited, as well as on the fragments of viral ...es that usually destroy infected cells. In a repo...hers from the Partners AIDS Research Center at Mas...
... lungs of patients suffering chronic obstructive p...elastic fibers, a new finding that contradicts the...ult lung. , The study "Evidence for attempted regi...s done by Jason Woods, Kristin Castillo, Alexander...sity, St. Louis, Mo.; Joel Cooper of the Universit...
Other Biology News:Encouraging results in pancreatic cancer research 2Interaction between lymph and liver cells may affect immune response 2Interaction between lymph and liver cells may affect immune response 3Early-stage immune system control of HIV may depend on inherited factors 2Early-stage immune system control of HIV may depend on inherited factors 3Lungs try to repair damaged elastic fibers 2
...alyzes the template-directed polymerization of nuc...olymerase I possesses a 3?5 exonuclease activity o...rate during DNA replication, and also contains a 5...to replace nucleotides in the growing strand of DN...
Request Info
supplied with 10x reaction buffer
from yeast/leuconostoc overproducer ATP: D-hexose 6- phosphotransferase/D-glucose-6-phosphate: NADP 1-oxidoreductase EC 2.7.1.1/1.1.1.49. One unit of HK will phosphorylate 1 mol of D-glucose in 1 min
Biology Products: